ClinConnect ClinConnect Logo
Search / Trial NCT04191395

Evolution and Treatments of Chronic Inflammatory Systemic Diseases

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE BESANCON · Dec 5, 2019

Trial Information

Current as of May 22, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is looking at chronic inflammatory diseases (CID) like Inflammatory Bowel Diseases (IBD), rheumatoid arthritis, and chronic skin conditions such as psoriasis. Researchers want to understand how these conditions are connected and how they can affect each other. The goal is to create a better understanding of these diseases, as many patients with one inflammatory condition may also experience other related issues. Currently, there's no shared database in France that collects information on these diseases, so this study aims to fill that gap.

To be eligible for the trial, participants should be patients treated for IBD (like Crohn's disease or ulcerative colitis), chronic inflammatory rheumatism (like rheumatoid arthritis or spondyloarthritis), or chronic inflammatory skin diseases (like psoriasis or Verneuil's disease) at the Besançon University Hospital. Participants can expect to contribute to valuable research that may help improve treatment options for themselves and others. It’s important to note that individuals who are in emergency situations or unable to provide consent cannot participate in this study.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients treated for IBD (MC, UC or indeterminate colitis) in the gastroenterology department of Besançon University Hospital
  • Subject meeting the clinical, morphological and histological diagnostic criteria for MC, UC or indeterminate colitis or
  • Patients treated for chronic inflammatory rheumatism (RA, SpA, PsA) in the rheumatology department of the University Hospital of Besançon Subject meeting the ACR 2010 classification criteria of RA or modified New York criteria of Ankylosing spondylitis or ASAS criteria of axial or peripheral SpA or CASPAR criteria of PsA or
  • Patients treated for chronic inflammatory skin disease (Psoriasis, Verneuil's disease) in the dermatology department of the University Hospital of Besançon
  • Exclusion Criteria:
  • Opposition of the patient
  • Patients in emergency situation, persons deprived of their liberty, protected minors or adults.

About Centre Hospitalier Universitaire De Besancon

The Centre Hospitalier Universitaire de Besançon (CHU de Besançon) is a leading academic medical center located in Besançon, France, dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, CHU de Besançon focuses on a wide range of medical disciplines, fostering collaboration between healthcare professionals and researchers to develop new therapeutic strategies and improve patient outcomes. With a commitment to rigorous scientific standards and ethical practices, the institution plays a vital role in translating research findings into practical applications, ultimately enhancing the quality of care provided to the community.

Locations

Besançon, , France

Besançon, , France

Patients applied

0 patients applied

Trial Officials

Clément Prati, Prof.

Principal Investigator

CHU Besançon

Lucine Vuitton, MD

Principal Investigator

CHU Besançon

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials